You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Details for Patent: 10,610,518

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,610,518 protect, and when does it expire?

Patent 10,610,518 protects VUITY and is included in one NDA.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 10,610,518

Title:	Presbyopia treatments
Abstract:	Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
Inventor(s):	Robinson; Michael R. (Huntington Beach, CA), Dibas; Mohammed (Corona, CA), Giyanani; Jaya (Irvine, CA), Gore; Anuradha (Aliso Viejo, CA), Lee; Sungwook (Orange, CA), Liu; Haixia (Irvine, CA), Morgan; Aileen (Rancho Santa Margarita, CA), Zhou; Jihao (Rancho Santa Margarita, CA)
Assignee:	ALLERGAN, INC. (Irvine, CA)
Application Number:	16/393,175
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 10,610,518

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VUITY	pilocarpine hydrochloride	SOLUTION;OPHTHALMIC	214028-001	Oct 28, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY	⤷ Try a Trial
Abbvie	VUITY	pilocarpine hydrochloride	SOLUTION;OPHTHALMIC	214028-001	Oct 28, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY	⤷ Try a Trial
Abbvie	VUITY	pilocarpine hydrochloride	SOLUTION;OPHTHALMIC	214028-001	Oct 28, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,610,518

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019261598	⤷ Try a Trial
Australia	2020203311	⤷ Try a Trial
Australia	2022201106	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.